Preparation of Carrageenan Fucoidan and Its Application in Dog and Cat Food

The sulfated sulfated ceramella fucoidan extracted by water alcohol precipitation combined with other ingredients, and the prepared urinary system care formula of dogs and cats solves the problems of poor palatability and high price of existing products, achieving effective prevention of cat lower urinary tract comprehensiveness Significance to significantly improve urinary tract health.

CN113519702BActive Publication Date: 2024-11-12HANGZHOU FURRYTAIL TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202110810281.7
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2021-07-17
Publication Date
2024-11-12
Estimated Expiration
2041-07-17

AI Technical Summary

Technical Problem

Existing urinary health products in dogs and cats have poor palatability and expensive problems, and lack of urinary care foods that can actively eat, making it difficult to effectively prevent diseases such as cats such as lower urinary tract syndrome (FLUTD).

Method used

A new sulfated carapacea fucoidan extracted by water alcohol precipitation method combines bovine kidney lyophilized powder, cranberry extract, blueberry extract, red raspberry extract, vitamin D, calcium iodate, sodium phosphate and Arginine, prepares a canine and cat urinary care formula, which forms an easy-to-eat product through high-temperature sterilization and homogenization treatment.

Benefits of technology

This formula not only increases the water intake of cats, inhibits the adhesion of pathogenic bacteria, improves vascular function, adjusts the calcium-phosphorus ratio, reduces the risk of urinary system diseases, significantly alleviates the symptoms of urinary tract infections and renal failure, and has preventive functions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN113519702B_ABST
    Figure CN113519702B_ABST
Patent Text Reader

Abstract

The invention discloses a preparation of fucoidan from serrata and its application in dog and cat food. A polysaccharide derived from serrata, named serrata fucoidan FT-POS, is a new type of serrata fucoidan extracted by water extraction and alcohol precipitation method, and its structure is mainly composed of L-fucose and galactose components. It is a new sulfated fucoidan, and FT-POS is a natural product. The purpose of the serrata fucoidan FT-POS is to prepare a urinary system care formula for dogs and cats, 66-70 parts of water, 6-20 parts of bovine kidney powder, 0.5-5 parts of serrata fucoidan FT-POS, 0.5-2 parts of cranberry extract, 0.5-2 parts of blueberry extract, 0.5-2 parts of red raspberry extract, 0.1-0.5 parts of vitamin D3, 0.5-1 parts of calcium iodate, and 0.5-1 parts of sodium phosphate. Wherein the serrata polysaccharide does not exceed 5% of the total mass of the oral care formula, and the ratio of total calcium to total phosphorus in the formula should be between 1:1 and 2:1. The invention can effectively prevent urinary system diseases, improve kidney inflammation, and enhance the anti-aging ability of kidney.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention belongs to the technical field of health products for the urinary system of dogs and cats, and particularly relates to the preparation of carrageenan fucoidan and its application in dog and cat food. Background Art

[0002] Feline lower urinary tract syndrome (FLUTD) is one of the most common diseases in domestic cats. FLUTD includes: ① feline urolithiasis, which refers to inflammation caused by stones or crystals in various parts of the urinary system; ② spontaneous cystitis (Feline idiopathic cystitis, FIC). In FLUTD cases, if no specific cause of clinical symptoms can be found, it is classified as spontaneous cystitis; ③ urinary tract infection (Urinary tract infection, UTI), an infectious disease caused by pathogens such as pathogens invading the urinary tract. The main causes of FLUTD include cats drinking less water, poor living environment hygiene, and low immunity due to old age. Among them, drinking less water is the special concern. Feeding wet food, setting up multiple drinking water points, and snacks that promote drinking water can improve the situation of cats not drinking water. Prevention of FLUTD is more important than treatment, and good prevention is crucial. Currently, most products for FLUTD prevention are prescription food and granular health products. Some products have poor palatability and are expensive. There are few urinary care foods that really allow cats to eat actively.

[0003] Pelvetia siliquosa Tsenget CFChang belongs to the Phaeophyta, Cyclosporeae, Fucales, Fucaceae, Pelvetia genus, also known as jade grass, six-cornered vegetable, and sea lettuce. Pelvetia siliquosa is widely distributed in the Liaodong Peninsula, Shandong, Zhejiang and other sea areas. There are rich polysaccharides in Staghorn algae, among which fucoidan is one of the important polysaccharide components in Staghorn algae. Its main monosaccharide is L-fucose. The functions of fucoidan are different due to the different degree of sulfation, the substitution position of sulfate groups and the molecular level. At present, the research and application of Staghorn algae are also mainly concentrated on the fucoidan in Staghorn algae polysaccharides. The research on Staghorn algae fucoidan mainly includes antioxidant, anti-tumor, lowering blood lipids and blood sugar, and immunity enhancement. The extraction processes of fucoidan include water bath method, acid extraction method, ultrasound-assisted method, water extraction and alcohol precipitation method, etc. There are few research reports on the new sulfated Staghorn algae fucoidan extracted by water extraction and alcohol precipitation in this patent. Staghorn algae fucoidan, together with concentrated tannic acid, arginine and trace elements such as potassium, has the potential to protect the kidneys of mammals and reduce the occurrence of urinary diseases. Summary of the invention

[0004] In order to overcome the deficiencies of the prior art, the present invention aims to provide a preparation method of carrageenan and its application in dog and cat food.

[0005] A formula for carrageenan-containing dog and cat urinary system care comprises the following raw materials in parts by mass: 66-90 parts of water, 6-20 parts of bovine kidney freeze-dried powder, 0.5-5 parts of carrageenan FT-POS, 0.5-2 parts of cranberry extract, 0.5-2 parts of blueberry extract, 0.5-2 parts of red raspberry extract, 0.1-0.5 parts of vitamin D3, 0.5-1 parts of calcium iodate, 0.5-1 parts of sodium phosphate, and 0.1-0.5 parts of arginine.

[0006] The bovine kidney freeze-dried powder is prepared by coarsely grinding fresh bovine kidney into pulp, sieving, high-temperature steaming, fine grinding and homogenization, and finally freeze-drying and further finely pulverizing.

[0007] The vitamin D family is vitamin D3.

[0008] The preparation method of the fucoidan FT-POS from Carrageenan in the dog and cat urinary system care formula is a water extraction and alcohol precipitation method. The fucoidan FT-POS is extracted from Carrageenan. The Carrageenan polysaccharide is firstly crudely extracted by a water extraction and alcohol precipitation method (ethanol precipitation of polysaccharide, ethanol, acetone and ether washing respectively), and then separated by an ion exchange chromatography column to obtain multiple sugar components, and the multiple sugar components are desalted and purified, and finally the monosaccharide component analysis is performed by a liquid chromatograph to obtain sulfated fucoidan.

[0009] A preparation method of the urinary system care formula:

[0010] ① Weighing: All raw materials are weighed according to the proportions stated in the formula and sterilized at 121°C for 30 minutes;

[0011] ② Premixing: premix the prepared raw materials of beef kidney powder, staghorn fucoidan FT-POS, cranberry extract, blueberry extract, red raspberry extract, vitamin D3, calcium iodate and sodium phosphate;

[0012] ③ Heating: Add water to raise the temperature (37-40℃), let it stand for 2 hours, then continue to heat the premix to 80-85℃ and let it stand for 1 hour;

[0013] ④Homogenization: The premix is ​​homogenized and cooled to room temperature.

[0014] ⑤ Molding: Fill, seal, sterilize and air-dry the premix, 10ml per can.

[0015] The beneficial effects of the present invention are as shown in Table 1:

[0016] Table 1. Function of each ingredient

[0017] Element Function Bovine Kidney Freeze-dried Powder Supplement trace elements and promote metabolism Carrageenan Fucoidan FT-POS Enhance kidney anti-aging function Cranberry Extract It is rich in concentrated tannic acid and has anti-bacterial adhesion properties. It can prevent pathogenic bacteria such as E. coli from adhering to the epithelial cells of the urethra and the bladder wall, allowing the pathogenic bacteria to flow out with urine, helping to reduce the occurrence of urinary tract infections. Blueberry Extract The anthocyanins and tannins found in blueberry extract may help prevent urinary tract infections. Cranberry Extract Cranberry extract is rich in ellagitannins, which helps improve the vascular function of healthy dogs and cats and also has antioxidant and anti-aging functions. Calcium iodate Supplement calcium and adjust the ratio of total calcium to total phosphorus between 1:1 and 2:1 to ensure normal nutrient absorption for dogs and cats and reduce urinary system diseases caused by calcium-phosphorus imbalance. Sodium phosphate Supplement phosphorus and adjust the ratio of total calcium to total phosphorus between 1:1 and 2:1 to ensure that the nutrients in the formula can be normally absorbed by dogs and cats, and reduce urinary system diseases caused by calcium-phosphorus imbalance. <![CDATA[Vitamin D3]]> Promote calcium absorption. Arginine Arginine is a key intermediate in the urea cycle, which can stimulate urea synthesis and activate enzymes to detoxify ammonia and synthesize urea. BRIEF DESCRIPTION OF THE DRAWINGS

[0018] Figure 1 This is the FT-POS structure diagram of Fucoidan from Carrageenan.

[0019] Figure 2 This is the electrospray mass spectrometry detection diagram of FT-POS of fucoidan from Carrageenan.

[0020] Figure 3 HE staining image: Fucoidan FT-POS from Psoralea corylifolia alleviates cyclophosphamide (CYX)-induced renal tubular necrosis in mice.

[0021] Figure 4 This is a TUNEL staining image: Fucoidan FT-POS from Psoralea corylifolia alleviates the level of apoptosis in mouse kidney cells induced by cyclophosphamide (CYX).

[0022] Figure 5 FT-POS from Fucoidan of Carrageenan can restore the GSH-PX enzyme activity inhibited by CYX (cyclophosphamide) and inhibit the increase of cellular malondialdehyde (MDA) caused by CYX.

[0023] Figure 6 The figure shows that FT-POS from Fucoidan of Carrageenan can increase the expression of anti-aging protein (Klotho) and antioxidant protein glutathione peroxidase 4 (GPX4) in the kidneys of mice. DETAILED DESCRIPTION

[0024] The present invention is further described below in conjunction with the accompanying drawings and embodiments.

[0025] Example 1: FT-POS extraction and structural analysis of fucoidan from Carrageenan

[0026] ① Decolorization: Fresh cercariae was decolorized three times with 85% ethanol to lighten the olive green color and obtain cercariae with lower pigment; ② Water extraction and alcohol precipitation method to extract polysaccharides: hot water pressurized polysaccharides, maintained at 105 ℃ for 3-4 hours until the supernatant was clear, filtered with diatomaceous earth to obtain the supernatant containing crude polysaccharides, the supernatant was divided into test tubes, and centrifuged at 8000rpm for 5 minutes to obtain the supernatant concentrate. The supernatant concentrate was dialyzed with a 3600Da dialysis bag for 24 hours, and dried with an infrared drying lamp to obtain the crude cercariae polysaccharide. ③ Separation and purification of crude polysaccharides from cercariae: several grams of crude polysaccharides from cercariae were collected by eluting with DEAE-Bio Gel Agarose FF gel with double distilled water, and then gradient eluted with 0.9% NaCl solution to collect the eluate for 3-5 times. Purified sulfated cercariae polysaccharide FT-POS was obtained after infrared drying. After component structure analysis, it was found that the polysaccharide theme was fucoidan. Thus, FT-POS was obtained as the target polysaccharide, i.e., cercariae fucoidan, and was named cercariae fucoidan FT-POS; ④ Preparation of hydrolysis components of cercariae fucoidan FT-POS: FT-POS was dissolved in double distilled water, and then fully mixed and hydrolyzed with cation exchange resin for 2.5-3 hours. After concentration, dialysis, and freeze-drying, sulfated fucoidan FT-POS was obtained; ⑤ Structural analysis of cercariae fucoidan FT-POS: The structure of FT-POS was analyzed by electrospray mass spectrometry, nuclear magnetic resonance detection, and other methods.

[0027] The test results are as follows: Figure 1 ), electrospray ionization mass spectrometry ( Figure 2 According to the analysis of ion group analysis (Table 2), FT-POS has a fucose skeleton and a small amount of galacturonic acid. In addition, according to the ion group analysis table (Table 2), FT-POS has different sulfated fucose oligomers, including monosulfide, disulfide, trisulfide, tetrasulfide, pentasulfide, etc., specifically monosulfated fucose oligomers (m / z 243.027 (-1), 389.090 (-1) and 535.130 (-1)), disulfated fucose oligomers (m / z 234.021 (-2) and 307.053 (-2)), trisulfated fucose oligomers (m / z 333.054 (-3)), disulfide, trisulfide, tetrasulfide, pentasulfide fucose oligomers (m / z 315.050 (-2), 285.039 (-3), 270.033 (-4) and 261.230 (-5)), the main structure of FT-POS is sulfated fucose oligomers (monosulfide or disulfide) and sulfated galactofucose oligomers (tetrasulfide), which is a new type of fucoidan from Carrageenan.

[0028] Table 2. Ionic composition of FT-POS polysaccharide from Carrageenan

[0029] Proton number / charge number (m / z) Charge number Components 234.021 2 [Fuc2(SO3H)2-2H]2- 243.027 1 [Fuc(SO3H)-H]- 261.230 5 [GalFuc5(SO3H)5-5H]5- 270.033 4 [GalFuc4(SO3H)4-4H]4- 285.039 3 [GalFuc3(SO3H)3-3H]3- 307.053 2 [Fuc3(SO3H)2-2H]2- 315.050 2 [GalFuc2(SO3H)2-2H]2- 333.054 3 [Fuc4(SO3H)5-3H]3- 389.090 1 [Fuc2(SO3H)-H]- 535.130 1 [Fuc3(SO3H)-H]-

[0030] Note: m / z is the ratio of the number of protons to the number of charges. The mass-to-charge ratio is an important parameter in mass spectrometry analysis.

[0031] Example 2: Revealing the mechanism of action of FT-POS, a polysaccharide from phlox serrata, in alleviating apoptosis of renal cells at the cellular level

[0032] Since the sampling of kidney samples is involved, dissection is required, so dogs and cats are not used for the experiment. The experiment uses a cyclophosphamide CTX immunosuppressive mouse model, the mouse strain is C57BL / 6, 5 weeks old, 60 males, the initial average weight is 22.12g, the dosage concentration is 80mg / kg, and each mouse is administered about 1.6mg / d. According to the dosage of 100ul, it needs to be prepared into a 16mg / ml stock solution, dissolved in physiological saline, vortexed and mixed, filtered and sterilized, and 100ul is injected intraperitoneally each time.

[0033] The experimental groups are shown in Table 3

[0034] Table 3. Experimental groups

[0035] Group Processing Quantity (pcs) Cycle (days) Blank control group (normal saline) 0.1 ml of normal saline was injected into the peritoneal cavity of mice for 7 consecutive days 20(n=4) 7 Model group (cyclophosphamide CYX) On days 3-5, mice were gavaged with CYX cyclophosphamide (80 mg / kg / d). 20(n=4) 7 Experimental group (polysaccharide + CYX cyclophosphamide (80 mg / kg / d)) The mice were intragastrically injected with CYX for 3-5 days, and then injected with FT-POS polysaccharide into the abdomen of the mice for 7 consecutive days. 20(n=4) 7

[0036] Clinical observations included the number of deaths, general health conditions and toxicity symptoms. The animals' conditions (including skin and fur condition, eyes and mucous membranes, respiratory system, circulatory system, autonomic movement, central nervous system and behavioral characteristics) were closely observed in the morning and afternoon every day, and the characteristics of adverse reactions, time of occurrence, severity and animal deaths were recorded in detail.

[0037] Experimental records: The health status of each group of mice was observed from the first day of feeding, and the number of deaths, food intake, body weight, etc. were counted.

[0038] Kidney sample collection: After the experiment, the mice were killed, and the kidneys were collected, quickly frozen in liquid nitrogen, and stored at -80 degrees for future use.

[0039] The experimental results are as follows: HE staining of the renal tubules of mice in different groups revealed that ( Figure 3 As shown in the figure, after cyclophosphamide (CYX) treatment, renal tubular edema occurred. After FT-POS treatment, the edema of the renal tubules was significantly alleviated, indicating that FT-POS, a polysaccharide from staghorn fucoidan, alleviated cyclophosphamide (CYX)-induced renal tubular necrosis in mice. Further TUNEL staining of kidney cells revealed that ( Figure 4As shown in the figure, compared with the control group, the apoptosis level of kidney cells increased significantly after CYX treatment, which was specifically manifested by the increase of brown spots. Compared with the CYX group, the apoptosis of kidney cells was alleviated after FT-POS treatment. At the same time, the ELISA kit detected that FT-POS, a polysaccharide from staghorn fucoidan, could restore the GSH-PX enzyme activity inhibited by CYX (cyclophosphamide) and inhibit the increase of cellular malondialdehyde (MDA) caused by CYX ( Figure 5 In summary, at the cellular level, FT-POS can alleviate renal cell apoptosis to a certain extent.

[0040] Example 3: The mechanism of action of FT-POS of fucoidan from phlox to improve the anti-oxidation and anti-aging of kidney cells revealed at the molecular level

[0041] ① Use a whole protein extraction kit to extract mouse kidney protein (including control group, model group and experimental group), centrifuge the crude protein extract and pack it, and put the supernatant containing protein into a clean centrifuge tube for subsequent experiments;

[0042] ② After protein extraction, concentration determination and dilution denaturation were performed. The protein concentration detection method referred to the instructions of the BCA protein concentration kit. The protein concentration of each group of protein samples was calculated according to the value of the microplate reader, and then the concentration of each sample was adjusted: according to the test results calculated previously, each sample was diluted to the same concentration with Lysis buffer, and 4xLoading buffer was added. The samples were heated at 95℃ for 10 min to denature the protein, and then cooled on ice and stored at -20℃.

[0043] ③The diluted samples are finally subjected to Western blot detection, including protein electrophoresis, membrane transfer and antibody reaction

[0044] ④ After the antibody reaction, put the membrane into the gel imaging analysis system, add luminescent liquid for development, and observe and take pictures. The experiment uses GAPDH as an internal reference to detect the expression levels of kidney anti-aging protein Klotho, antioxidant protein GPX4 and PRX5.

[0045] The test results are as follows: Figure 6As shown in the figure, compared with the control group, after CYX treatment, the expression of the kidney anti-aging protein Klotho decreased significantly, and the injection of FT-POS significantly increased the expression of Klotho, indicating that FT-POS can improve the decrease of kidney anti-aging protein caused by CYX. Similarly, compared with the control group, after CYX treatment, the expression of the antioxidant protein glutathione peroxidase GPX4 decreased significantly, and the injection of FT-POS significantly increased the expression of GPX4, but had no significant effect on another antioxidant protein Peroxiredoxin5 (PRX5). Overall, at the molecular level, FT-POS can improve the decrease of kidney antioxidant capacity caused by CYX.

[0046] Example 4: Preparation of a nursing formula containing FT-POS polysaccharide from staghorn fucoidan and its application effect

[0047] ① Formula proofing with different ratios

[0048] Sample formula 1: 90 parts of water, 6 parts of bovine kidney freeze-dried powder, 0.5 parts of fucoidan FT-POS, 0.5 parts of cranberry extract, 0.5 parts of blueberry extract, 0.5 parts of red raspberry extract, 0.1 parts of vitamin D3, 0.5 parts of calcium iodate, 0.5 parts of sodium phosphate, and 0.1 parts of arginine.

[0049] Sample formula 2: 76 parts of water, 14 parts of bovine kidney freeze-dried powder, 2.5 parts of fucoidan FT-POS, 1.5 parts of cranberry extract, 1.5 parts of blueberry extract, 1.5 parts of red raspberry extract, 0.2 parts of vitamin D3, 0.8 parts of calcium iodate, 0.7 parts of sodium phosphate, and 0.3 parts of arginine.

[0050] Sample formula three: 66 parts of water, 20 parts of bovine kidney freeze-dried powder, 5 parts of fucoidan FT-POS, 2 parts of cranberry extract, 2 parts of blueberry extract, 2 parts of red raspberry extract, 0.5 parts of vitamin D3, 1 part of calcium iodate, 1 part of sodium phosphate, and 0.5 parts of arginine.

[0051] ③ Prepare samples according to the three formulas respectively, and then conduct sensory and palatability tests, and select one formula for the next feeding test.

[0052] ④ According to the medical history, clinical symptoms, clinical tests and B-ultrasound test results, 18 cats were divided into two groups, 9 cats in each group, a healthy group and a chronic renal failure group (CRF). They were uniformly fed with brand A cat food (low magnesium content) and the feeding environment was consistent. The experimental period was 2 weeks. Each cat was supplemented with 10 ml of urine sample every day. Blood was collected before and after the experiment, and the initial and final weights were calculated. The ELISA kit, sarcosine oxidase method, and urease-glutamate dehydrogenase method were used to determine the concentrations of dimethylarginine (SDMA), urea nitrogen (Urea), creatinine (Crea), total protein (TP) and albumin (ALB) in serum, which were related indicators of chronic renal damage. The entire blood collection process was carried out in a qualified pet hospital and was sampled by professional veterinary staff to minimize the stress on the cats.

[0053] Table 4. Results of serum biochemical indexes of cats in different groups

[0054]

[0055] The evaluation results of the formulas are as follows: Formula 1 has good palatability and a thinner consistency, Formula 2 also has good palatability and a moderate concentration, and Formula 3 is relatively viscous, making it difficult for cats to lick it and sticking to their teeth. The reason may be that the high content of fucoidan increases the viscosity. After comprehensive consideration, Formula 2 was selected for the feeding test among the three formulas. The reason for the selection is that Formula 2 has a higher content of effective ingredients than Formula 1 while maintaining good palatability.

[0056] The feeding results are as follows: After the healthy group was fed 10ml of formula 2 daily for 14 days, there was no significant change in the indicators related to kidney damage, and the ALB and TP in the serum decreased to a certain extent, by 3.4% and 6.0%, respectively, and within a reasonable range, but not significantly overall, and there was no significant change in the weight of the healthy group. After the CRF group was fed 10ml of formula 2 for 14 days, there was no significant change in weight, and some indicators related to kidney damage decreased significantly, among which SDMA decreased by 2.2% (no significant change), Urea decreased by 7.7%, Crea decreased by 9.3%, TP decreased by 10.6%, ALB decreased by 8.5%, and the weight increased slightly. This shows that the urinary system care formula can alleviate chronic renal failure to a certain extent, but overall the indicators related to kidney damage are higher than the normal range, which belongs to the sub-healthy state. The urinary care formula containing FT-POS has a certain preventive effect on renal failure and a certain improvement effect on cats with renal failure, but it cannot completely cure it, so the formula-related products are defined as functional foods that assist or prevent urinary-related diseases, not medicinal. This trial provides a reference case for urinary system care and is suitable for cats with urinary system damage or functional decline (such as elderly cats). If thorough treatment is required, relevant medications or prescription food are required.

[0057] The above test results and examples are specific descriptions of the present invention, but the present invention is not limited to the above specific implementation methods. The above test results are only the ratios and product forms of some formulas, and are not limited to these ratios and forms. The same ratio can be made into products in different forms (freeze-dried, powder, capsule, liquid). For ordinary technicians in the field, other different forms of changes or modifications can be made on the basis of the above description. All deformations that ordinary technicians in the field can directly derive or associate from the content disclosed in the present invention should be considered as the protection scope of the present invention. The protection scope of the present invention is given by the attached claims and any equivalents thereof.

Claims

1. A formula for caraway system care for dogs and cats containing FT-POS, characterized in that: The composition is composed of the following components by mass: 66-90 parts of water, 6-20 parts of bovine kidney freeze-dried powder, 0.5-5 parts of fucoidan FT-POS, 0.5-2 parts of cranberry extract, 0.5-2 parts of blueberry extract, 0.5-2 parts of red raspberry extract, 0.1-0.5 parts of vitamin D3, 0.5-1 parts of calcium iodate, 0.5-1 parts of sodium phosphate, and 0.1-0.5 parts of arginine; The fucoidan FT-POS is extracted from the fucoidan by using a water extraction and alcohol precipitation method.

2. The urinary system care formula for dogs and cats according to claim 1, characterized in that: The bovine kidney freeze-dried powder is prepared by coarsely grinding fresh bovine kidney into pulp, sieving, high-temperature steaming, fine grinding and homogenization, and finally crushing into 100-mesh bovine kidney freeze-dried powder at a temperature of minus 20°C.

3. The urinary system care formula for dogs and cats according to claim 1, characterized in that: The mass ratio of total calcium to total phosphorus in the added calcium iodate and sodium phosphate is 1:1~2:

1.

4. The urinary system care formula for dogs and cats according to claim 1, characterized in that: The vitamin D3 content does not exceed 0.5% of the total mass.

5. A method for preparing the dog and cat urinary system care formula according to claim 1, characterized in that: ① Weighing: All raw materials are weighed according to the formula and sterilized at 121℃ for 30 minutes; ② Premixing: premix the prepared raw materials of beef kidney powder, staghorn fucoidan FT-POS, cranberry extract, blueberry extract, red raspberry extract, vitamin D3, calcium iodate and sodium phosphate; ③ Heating: Add water and heat to 37-40℃, let stand for 2 hours, then continue to heat the premix to 80-85℃ and let stand for 1 hour; ④Homogenization: The premix is ​​homogenized and cooled to room temperature; ⑤ Molding: Filling, sealing, sterilizing and air-drying the premix.